National Research (NRC)
Market Price (4/13/2026): $16.53 | Market Cap: $360.0 MilSector: Health Care | Industry: Health Care Technology
National Research (NRC)
Market Price (4/13/2026): $16.53Market Cap: $360.0 MilSector: Health CareIndustry: Health Care Technology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 6.3%, Dividend Yield is 3.1% Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 19%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 11% Megatrend and thematic driversMegatrends include Digital Health & Telemedicine. Themes include Health Data Analytics, and AI in Healthcare Management. | Weak multi-year price returns2Y Excs Rtn is -84%, 3Y Excs Rtn is -125% | Expensive valuation multiplesP/EPrice/Earnings or Price/(Net Income) is 31x Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -4.0%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -3.2%, Rev Chg QQuarterly Revenue Change % is -4.6% Key risksNRC key risks include [1] a significant and ongoing earnings contraction cycle, Show more. |
| Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 6.3%, Dividend Yield is 3.1% |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 19%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 11% |
| Megatrend and thematic driversMegatrends include Digital Health & Telemedicine. Themes include Health Data Analytics, and AI in Healthcare Management. |
| Weak multi-year price returns2Y Excs Rtn is -84%, 3Y Excs Rtn is -125% |
| Expensive valuation multiplesP/EPrice/Earnings or Price/(Net Income) is 31x |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -4.0%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -3.2%, Rev Chg QQuarterly Revenue Change % is -4.6% |
| Key risksNRC key risks include [1] a significant and ongoing earnings contraction cycle, Show more. |
Qualitative Assessment
AI Analysis | Feedback
National Research (NRC) stock has lost about 10% since 12/31/2025 because of the following key factors:
1. National Research reported a year-over-year revenue decline of 5% for Q4 2025, reaching $35.2 million, and a 4% decline for the full year 2025 to $137.4 million. This underperformance, which management attributed to unusually heavy Total Recurring Contract Value (TRCV) attrition in the latter half of 2024, triggered a significant 19.54% drop in the stock's aftermarket trading following the earnings announcement on February 3, 2026.
2. The company experienced a notable decline in profit margins, with its net profit margin decreasing to 11.6% over the last twelve months, compared to 18.8% in the prior year. This indicates deteriorating profitability and a sustained trend, as trailing twelve-month earnings have declined at an annualized rate of 12.4% over the past five years.
Show more
1. National Research reported a year-over-year revenue decline of 5% for Q4 2025, reaching $35.2 million, and a 4% decline for the full year 2025 to $137.4 million. This underperformance, which management attributed to unusually heavy Total Recurring Contract Value (TRCV) attrition in the latter half of 2024, triggered a significant 19.54% drop in the stock's aftermarket trading following the earnings announcement on February 3, 2026.
2. The company experienced a notable decline in profit margins, with its net profit margin decreasing to 11.6% over the last twelve months, compared to 18.8% in the prior year. This indicates deteriorating profitability and a sustained trend, as trailing twelve-month earnings have declined at an annualized rate of 12.4% over the past five years.
Show more
Stock Movement Drivers
Fundamental Drivers
The -11.4% change in NRC stock from 12/31/2025 to 4/12/2026 was primarily driven by a -28.2% change in the company's Net Income Margin (%).| (LTM values as of) | 12312025 | 4122026 | Change |
|---|---|---|---|
| Stock Price ($) | 18.60 | 16.48 | -11.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 139 | 137 | -1.2% |
| Net Income Margin (%) | 11.8% | 8.4% | -28.2% |
| P/E Multiple | 25.2 | 30.9 | 23.0% |
| Shares Outstanding (Mil) | 22 | 22 | 1.6% |
| Cumulative Contribution | -11.4% |
Market Drivers
12/31/2025 to 4/12/2026| Return | Correlation | |
|---|---|---|
| NRC | -11.4% | |
| Market (SPY) | -5.4% | 22.3% |
| Sector (XLV) | -4.8% | -6.6% |
Fundamental Drivers
The 31.3% change in NRC stock from 9/30/2025 to 4/12/2026 was primarily driven by a 95.0% change in the company's P/E Multiple.| (LTM values as of) | 9302025 | 4122026 | Change |
|---|---|---|---|
| Stock Price ($) | 12.56 | 16.48 | 31.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 140 | 137 | -2.1% |
| Net Income Margin (%) | 12.8% | 8.4% | -33.9% |
| P/E Multiple | 15.9 | 30.9 | 95.0% |
| Shares Outstanding (Mil) | 23 | 22 | 4.0% |
| Cumulative Contribution | 31.3% |
Market Drivers
9/30/2025 to 4/12/2026| Return | Correlation | |
|---|---|---|
| NRC | 31.3% | |
| Market (SPY) | -2.9% | 12.7% |
| Sector (XLV) | 6.3% | 2.3% |
Fundamental Drivers
The 33.2% change in NRC stock from 3/31/2025 to 4/12/2026 was primarily driven by a 165.4% change in the company's P/E Multiple.| (LTM values as of) | 3312025 | 4122026 | Change |
|---|---|---|---|
| Stock Price ($) | 12.37 | 16.48 | 33.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 143 | 137 | -4.0% |
| Net Income Margin (%) | 17.3% | 8.4% | -51.3% |
| P/E Multiple | 11.7 | 30.9 | 165.4% |
| Shares Outstanding (Mil) | 23 | 22 | 7.2% |
| Cumulative Contribution | 33.2% |
Market Drivers
3/31/2025 to 4/12/2026| Return | Correlation | |
|---|---|---|
| NRC | 33.2% | |
| Market (SPY) | 16.3% | 24.0% |
| Sector (XLV) | 2.3% | 16.0% |
Fundamental Drivers
The -58.4% change in NRC stock from 3/31/2023 to 4/12/2026 was primarily driven by a -59.8% change in the company's Net Income Margin (%).| (LTM values as of) | 3312023 | 4122026 | Change |
|---|---|---|---|
| Stock Price ($) | 39.64 | 16.48 | -58.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 152 | 137 | -9.4% |
| Net Income Margin (%) | 21.0% | 8.4% | -59.8% |
| P/E Multiple | 30.7 | 30.9 | 0.7% |
| Shares Outstanding (Mil) | 25 | 22 | 13.2% |
| Cumulative Contribution | -58.4% |
Market Drivers
3/31/2023 to 4/12/2026| Return | Correlation | |
|---|---|---|
| NRC | -58.4% | |
| Market (SPY) | 63.3% | 23.9% |
| Sector (XLV) | 19.1% | 24.2% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| NRC Return | -2% | -8% | 10% | -54% | 10% | -8% | -55% |
| Peers Return | 5% | -32% | -5% | -24% | -44% | -46% | -84% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -0% | 82% |
Monthly Win Rates [3] | |||||||
| NRC Win Rate | 58% | 50% | 33% | 33% | 50% | 75% | |
| Peers Win Rate | 45% | 40% | 52% | 40% | 33% | 10% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| NRC Max Drawdown | -6% | -23% | 0% | -56% | -42% | -36% | |
| Peers Max Drawdown | -17% | -52% | -36% | -41% | -50% | -47% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -7% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: HSTM, PHR, DH, HCAT, EVH.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 4/10/2026 (YTD)
How Low Can It Go
| Event | NRC | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -41.5% | -25.4% |
| % Gain to Breakeven | 71.0% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -50.2% | -33.9% |
| % Gain to Breakeven | 100.9% | 51.3% |
| Time to Breakeven | Not Fully Recovered days | 148 days |
| 2018 Correction | ||
| % Loss | -26.4% | -19.8% |
| % Gain to Breakeven | 35.9% | 24.7% |
| Time to Breakeven | 175 days | 120 days |
Compare to HSTM, PHR, DH, HCAT, EVH
In The Past
National Research's stock fell -41.5% during the 2022 Inflation Shock from a high on 8/23/2021. A -41.5% loss requires a 71.0% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About National Research (NRC)
National Research Corporation provides analytics and insights that facilitate measurement and enhancement of the patient and employee experience in the United States and Canada. Its portfolio of subscription-based solutions provides actionable information and analysis to healthcare organizations across a range of mission-critical, constituent-related elements, including patient experience, service recovery, care transitions, health risk assessments, employee engagement, reputation management, and brand loyalty. The company also offers market insights solutions that allow the tracking of awareness, perception, and consistency of healthcare brands; assessment of competitive differentiators; and enhanced segmentation tools to evaluate needs, wants, and behaviors of communities through real-time competitive assessments and enhanced segmentation tools. In addition, it provides experience solutions, such as patient and resident experience, workforce engagement, health risk assessments, transitions, and improvement tools. Further, the company offers health risk assessment solutions that enable clients to segment populations and manage care for those who are most at risk, engage individuals, enhance preventative care, and manage wellness programs; and transitions solutions, which enable organizations to identify and manage high-risk patients to reduce readmissions, enhance patient satisfaction and support safe care transitions. Additionally, it provides transparency solutions that allow healthcare organizations to share picture of their organization and ensure content informs in consumer decision-making; and governance solutions for not-for-profit hospital and health system boards of directors, executives, and physician leadership. The company serves integrated health systems, post-acute providers, and payer organizations. National Research Corporation was founded in 1981 and is headquartered in Lincoln, Nebraska.
AI Analysis | Feedback
Analogy 1: Qualtrics for healthcare organizations
Analogy 2: A specialized Gartner for healthcare insights and strategy
AI Analysis | Feedback
- Patient & Resident Experience Solutions: Provide analytics and insights to measure and enhance patient and resident satisfaction, including tools for service recovery.
- Workforce Engagement Solutions: Offer analytics and insights to improve employee satisfaction and engagement within healthcare organizations.
- Health Risk Assessment Solutions: Enable clients to segment populations, identify at-risk individuals, and support preventative care and wellness programs.
- Care Transitions Solutions: Help organizations manage high-risk patients to reduce readmissions and ensure safe care transitions.
- Market & Brand Insights Solutions: Track healthcare brand awareness, perception, and competitive differentiators, while also managing reputation and brand loyalty.
- Transparency Solutions: Empower healthcare organizations to share public information to inform consumer decision-making.
- Governance Solutions: Offer services and insights for the boards, executives, and physician leadership of not-for-profit health systems.
AI Analysis | Feedback
National Research Corporation (NRC) primarily serves other companies within the healthcare sector. Its major customer categories include:
- Integrated health systems
- Post-acute providers
- Payer organizations
AI Analysis | Feedback
nullAI Analysis | Feedback
Trent Green, Chief Executive Officer
Appointed as Chief Executive Officer effective June 1, 2025, succeeding the company's founder. He directly owns approximately 2.21% of the company's shares.
Shane Harrison, Chief Financial Officer
Joined the executive team around September 25, 2025, bringing over 25 years of finance and strategy experience.
Mike Hays, Chairman of the Board
Founder of National Research Corporation in 1981, he served as Chief Executive Officer and President for over four decades before transitioning to Chairman of the Board in June 2025. Prior to founding NRC Health, Mr. Hays gained experience as Vice President and Director of SRI Research Center, Inc., which is now known as the Gallup Organization. He is also a Director at Nebraska Global Investment Co. LLC, a firm that invests in technology companies.
Helen L. Hrdy, Chief Operating Officer
A key executive whose compensation was adjusted with a grant of 100,000 shares of common stock in April 2025.
Jordan N. Freeman, Chief Accounting Officer
Appointed in April 2025, she manages the company's accounting operations.
AI Analysis | Feedback
The key risks to National Research Corporation (NRC) include:
- Intense Competition, Market Saturation, and Dependence on Contract Renewals: National Research operates in a highly competitive healthcare analytics market, with its specialized focus on patient experience analytics potentially limiting its total addressable market. This makes the company vulnerable to market saturation and shifts in healthcare policy. The subscription-based revenue model also means the company is heavily dependent on customer retention and contract renewals. Larger, more diversified competitors can offer bundled solutions, potentially impacting NRC's pricing power and growth prospects. Recent financial results have shown declining revenue and operating income, suggesting challenges in sales and retention.
- Regulatory and Reimbursement Changes in the Healthcare Industry: As a provider of healthcare analytics and insights, National Research Corporation is directly exposed to changes in healthcare policy and regulations in both the United States and Canada. Shifts in these regulatory and reimbursement landscapes could significantly impact the demand for its services or necessitate substantial adjustments to its existing offerings.
- Cybersecurity and Data Privacy Threats: National Research handles sensitive patient and employee data for healthcare organizations. This exposes the company to significant risks related to IT system failures, cybersecurity breaches, or cyberattacks. A security incident could lead to material financial and reputational damage, as well as potential regulatory penalties due to the highly regulated nature of healthcare data.
AI Analysis | Feedback
The rapid advancement and integration of artificial intelligence (AI) and machine learning (ML) technologies within the healthcare IT landscape represent a clear emerging threat. As AI and ML tools become more sophisticated, they can automate, enhance, and provide deeper, more real-time insights into patient experience, health risk assessments, workforce engagement, and market analytics. This could enable healthcare organizations to develop more robust in-house analytics capabilities or shift demand towards AI-native solutions offered by new entrants or large technology companies, potentially diminishing the value proposition and demand for NRC's traditional subscription-based analytics and insights solutions.
AI Analysis | Feedback
National Research Corporation (NRC) operates in several key addressable markets within the healthcare sector of the United States and Canada. Based on available data, the market sizes for their main products and services are as follows:
- Patient Experience and Engagement Solutions: The U.S. patient engagement solutions market was valued at approximately USD 7.59 billion in 2024 and is projected to reach USD 22.41 billion by 2030, growing at a Compound Annual Growth Rate (CAGR) of 19.77% from 2025 to 2030. Another estimate places the U.S. patient engagement solutions market at USD 7.40 billion in 2025, expected to increase to USD 25.21 billion by 2034, with a CAGR of 14.68% from 2025 to 2034. For North America, the patient engagement solutions market generated USD 12,045.6 million (USD 12.04 billion) in 2024 and is anticipated to reach USD 36,042.2 million (USD 36.04 billion) by 2030, with a CAGR of 20% from 2025 to 2030.
- Employee Engagement Solutions (Healthcare Specific): The global employee engagement market is projected to grow from USD 1.10 billion in 2025 to USD 2.58 billion by 2031, at a CAGR of 15.28%. North America held the largest market share in 2024. Specifically within the healthcare sector, employee engagement programs are forecast to experience the highest CAGR of 19.12%, with the market size for healthcare programs expected to double by 2031. The global employee engagement software market was valued at USD 1.22 billion in 2025 and is projected to reach USD 4.47 billion by 2034, growing at a CAGR of 15.30%. North America accounted for 31.40% of the global market in 2025, with a valuation of USD 0.38 billion.
- Health Risk Assessment (HRA) Solutions: Within the broader global corporate wellness market, the Health Risk Assessment (HRAs) segment held the largest market share of 21.45% in 2025. The global corporate wellness market itself was valued at USD 68.02 billion in 2025. North America dominated the corporate wellness market with a 40.28% share in 2025.
- Care Transitions Solutions: The U.S. transitional care management services market is expected to reach USD 319.4 million by 2030, demonstrating a CAGR of 17.3% from 2022 to 2030. Globally, the transitional care management services market is estimated at USD 265.74 billion in 2025 and is projected to reach USD 724.71 billion by 2032, with a CAGR of 15.4% from 2025 to 2032. North America is anticipated to hold 44.4% of this market share in 2025. More broadly, the U.S. care management solutions market was valued at USD 6.63 billion in 2024 and is projected to grow to USD 14.50 billion by 2030, at a CAGR of 14.1%.
- Healthcare Analytics and Market Insights Solutions: The U.S. healthcare analytics market was valued at USD 15.85 billion in 2024, and is projected to grow to USD 59.68 billion by 2030, at a CAGR of 24.9% from 2024 to 2030. Another report estimates the U.S. healthcare analytics market size at USD 21.21 billion in 2024, projected to reach USD 67.48 billion by 2033, with a CAGR of 12.76% from 2025 to 2033. The North America healthcare analytics market was valued at USD 14.87 billion in 2025 and is projected to grow to USD 17.89 billion in 2026.
- Reputation Management Solutions (Healthcare Specific): The global online reputation management market was valued at USD 6.88 billion in 2025 and is estimated to grow to USD 14.01 billion by 2031, with a CAGR of 12.59% from 2026 to 2031. North America accounted for 38.20% of the revenue in 2025. The healthcare sector within this market is projected to grow at an 18.82% CAGR.
- Governance Solutions (Healthcare Risk Management): The hospital risk management market is estimated to generate USD 1.8 billion in revenue in 2024 and is projected to grow to USD 5.0 billion by 2032, exhibiting a CAGR of 13.9% from 2025 to 2032. North America dominates this market.
AI Analysis | Feedback
National Research Corporation (NASDAQ: NRC), operating as NRC Health, anticipates future revenue growth over the next 2-3 years to be driven by several key factors:
- Growth in Total Recurring Contract Value (TRCV): NRC Health expects continued expansion of its Total Recurring Contract Value (TRCV), a leading indicator of future subscription revenue. The company reported TRCV reaching an all-time high of over $152 million as of March 4, 2026, representing a 13% year-over-year increase. This growth is attributed to strong, long-term relationships with health system partners and effective execution across sales and customer success teams, indicating both increased penetration with existing clients and the acquisition of new customers.
- Product Innovation, including AI-enabled Solutions: The company is investing in and expanding new healthcare analytics solutions, with a particular focus on integrating artificial intelligence (AI) capabilities. This innovation aims to capture emerging trends, address evolving customer needs, and tap into new market segments. An example of this is the enhanced workflow-driven solution "Rounding," which saw its TRCV nearly double in 2025.
- Strategic Acquisitions and Investments: NRC Health plans to continue pursuing complementary strategic acquisitions and investments. This strategy is intended to further fuel growth, expand the company's technology offerings, and enhance its overall capabilities within the healthcare analytics market.
AI Analysis | Feedback
Share Repurchases
- In April 2025, National Research's Board authorized and completed the repurchase of 1 million shares by September 30, 2025.
- As of March 9, 2026, the Board of Directors authorized a new stock repurchase program of up to $60 million of outstanding common stock through March 31, 2028.
- No share repurchases occurred in the fourth quarter of 2025.
Share Issuance
- In March 2026, an Executive Vice President was granted 60,000 restricted stock units under the 2025 Omnibus Incentive Plan, vesting in installments from 2027 to 2029.
- In February 2026, a director received 8,819 stock options.
Outbound Investments
- National Research plans to continue pursuing complementary acquisitions and investments to fuel growth and expand its technology and capabilities.
- The company acquired a "rounding tool" in 2024 or 2025 as part of its product innovation strategy, which also includes AI-enabled offerings.
Capital Expenditures
- Cash paid for capital expenditures totaled $10.7 million in the year ended December 31, 2025.
- These expenditures were focused on building improvements, furniture and equipment, computer hardware, and costs associated with software development for its Human Understanding® solutions.
- The company is investing in its business and technology to innovate new capabilities, including AI-enabled offerings, to accelerate growth.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| National Research Earnings Notes | 12/16/2025 | |
| National Research Stock Jump Looks Great, But How Secure Is That Gain? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to NRC.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 03312026 | PGNY | Progyny | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 0.0% | 0.0% | 0.0% |
| 03272026 | CNC | Centene | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 2.3% | 2.3% | -0.6% |
| 03272026 | OSCR | Oscar Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 3.0% | 3.0% | -2.6% |
| 03202026 | WAT | Waters | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | -0.4% | -0.4% | -3.3% |
| 03202026 | GILD | Gilead Sciences | Quality | Q | Momentum | UpsideQuality Stocks with Momentum and UpsideBuying quality stocks with strong momentum but still having room to run | 1.6% | 1.6% | -2.2% |
| 09302019 | NRC | National Research | Quality | Q | Momentum | UpsideQuality Stocks with Momentum and UpsideBuying quality stocks with strong momentum but still having room to run | -21.7% | -14.1% | -39.2% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 5.20 |
| Mkt Cap | 0.3 |
| Rev LTM | 308 |
| Op Inc LTM | -13 |
| FCF LTM | 23 |
| FCF 3Y Avg | 26 |
| CFO LTM | 46 |
| CFO 3Y Avg | 42 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | -1.2% |
| Rev Chg 3Y Avg | 4.3% |
| Rev Chg Q | -2.9% |
| QoQ Delta Rev Chg LTM | -0.8% |
| Op Mgn LTM | -1.2% |
| Op Mgn 3Y Avg | -4.6% |
| QoQ Delta Op Mgn LTM | -1.0% |
| CFO/Rev LTM | 17.8% |
| CFO/Rev 3Y Avg | 12.8% |
| FCF/Rev LTM | 10.8% |
| FCF/Rev 3Y Avg | 6.5% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 0.3 |
| P/S | 0.7 |
| P/EBIT | -0.5 |
| P/E | 15.3 |
| P/CFO | 8.0 |
| Total Yield | -70.5% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | 3.0% |
| D/E | 1.0 |
| Net D/E | 0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -19.2% |
| 3M Rtn | -48.7% |
| 6M Rtn | -63.1% |
| 12M Rtn | -65.0% |
| 3Y Rtn | -82.9% |
| 1M Excs Rtn | -22.1% |
| 3M Excs Rtn | -46.6% |
| 6M Excs Rtn | -66.1% |
| 12M Excs Rtn | -100.5% |
| 3Y Excs Rtn | -148.4% |
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Analytics and insight solutions designed to measure and improve patient and employee experience for | 143 | 149 | 152 | 148 | 133 |
| Total | 143 | 149 | 152 | 148 | 133 |
| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Analytics and insight solutions designed to measure and improve patient and employee experience for | 40 | ||||
| Total | 40 |
| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Analytics and insight solutions designed to measure and improve patient and employee experience for | 31 | ||||
| Total | 31 |
Price Behavior
Price Behavior
| Market Price | $16.48 | |
| Market Cap ($ Bil) | 0.4 | |
| First Trading Date | 05/23/2013 | |
| Distance from 52W High | -26.0% | |
| 50 Days | 200 Days | |
| DMA Price | $15.66 | $15.49 |
| DMA Trend | up | down |
| Distance from DMA | 5.2% | 6.4% |
| 3M | 1YR | |
| Volatility | 74.4% | 56.1% |
| Downside Capture | 0.98 | 0.62 |
| Upside Capture | 159.58 | 144.80 |
| Correlation (SPY) | 20.7% | 25.0% |
NRC Betas & Captures as of 3/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.03 | 1.38 | 1.31 | 0.63 | 0.73 | 0.72 |
| Up Beta | 0.43 | 1.38 | 2.42 | 0.32 | 0.71 | 0.83 |
| Down Beta | 0.30 | -0.35 | 0.50 | 0.17 | 0.31 | 0.31 |
| Up Capture | 238% | 236% | 172% | 158% | 131% | 29% |
| Bmk +ve Days | 7 | 16 | 27 | 65 | 139 | 424 |
| Stock +ve Days | 13 | 22 | 33 | 67 | 131 | 363 |
| Down Capture | -175% | 188% | 144% | 57% | 100% | 103% |
| Bmk -ve Days | 12 | 23 | 33 | 58 | 110 | 323 |
| Stock -ve Days | 9 | 20 | 30 | 57 | 118 | 381 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with NRC | |
|---|---|---|---|---|
| NRC | 42.7% | 57.1% | 0.84 | - |
| Sector ETF (XLV) | 12.3% | 16.8% | 0.52 | 19.2% |
| Equity (SPY) | 31.2% | 17.3% | 1.47 | 28.0% |
| Gold (GLD) | 60.1% | 27.8% | 1.69 | -19.9% |
| Commodities (DBC) | 29.8% | 16.6% | 1.58 | -14.9% |
| Real Estate (VNQ) | 21.3% | 15.2% | 1.07 | 15.2% |
| Bitcoin (BTCUSD) | -4.3% | 43.7% | 0.02 | 8.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with NRC | |
|---|---|---|---|---|
| NRC | -17.1% | 40.6% | -0.34 | - |
| Sector ETF (XLV) | 6.3% | 14.6% | 0.25 | 26.8% |
| Equity (SPY) | 11.1% | 17.0% | 0.50 | 27.4% |
| Gold (GLD) | 22.1% | 17.8% | 1.02 | -7.2% |
| Commodities (DBC) | 11.8% | 18.8% | 0.52 | -4.0% |
| Real Estate (VNQ) | 3.7% | 18.8% | 0.10 | 25.9% |
| Bitcoin (BTCUSD) | 4.3% | 56.5% | 0.30 | 12.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with NRC | |
|---|---|---|---|---|
| NRC | 2.6% | 39.5% | 0.20 | - |
| Sector ETF (XLV) | 9.8% | 16.5% | 0.48 | 36.8% |
| Equity (SPY) | 13.8% | 17.9% | 0.66 | 40.3% |
| Gold (GLD) | 14.2% | 15.9% | 0.74 | -2.2% |
| Commodities (DBC) | 8.6% | 17.6% | 0.41 | 7.9% |
| Real Estate (VNQ) | 5.1% | 20.7% | 0.22 | 38.9% |
| Bitcoin (BTCUSD) | 67.6% | 66.9% | 1.07 | 14.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 2/3/2026 | -19.5% | -29.8% | -40.1% |
| 10/27/2025 | 16.0% | 16.0% | 57.8% |
| 7/28/2025 | -4.8% | -2.0% | 10.4% |
| 4/28/2025 | 9.5% | 17.9% | 22.7% |
| 1/27/2025 | -11.9% | -12.7% | -20.7% |
| 10/25/2024 | 4.5% | 1.1% | 9.4% |
| 8/6/2024 | -9.5% | -5.1% | -5.0% |
| 5/7/2024 | -16.5% | -12.2% | -24.7% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 11 | 13 | 14 |
| # Negative | 13 | 11 | 10 |
| Median Positive | 3.6% | 4.8% | 9.1% |
| Median Negative | -4.1% | -4.5% | -10.0% |
| Max Positive | 16.0% | 17.9% | 57.8% |
| Max Negative | -19.5% | -29.8% | -40.1% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 12/31/2025 | 03/05/2026 | 10-K |
| 09/30/2025 | 11/07/2025 | 10-Q |
| 06/30/2025 | 08/08/2025 | 10-Q |
| 03/31/2025 | 05/09/2025 | 10-Q |
| 12/31/2024 | 03/17/2025 | 10-K |
| 09/30/2024 | 11/08/2024 | 10-Q |
| 06/30/2024 | 08/08/2024 | 10-Q |
| 03/31/2024 | 05/09/2024 | 10-Q |
| 12/31/2023 | 02/27/2024 | 10-K |
| 09/30/2023 | 11/09/2023 | 10-Q |
| 06/30/2023 | 08/04/2023 | 10-Q |
| 03/31/2023 | 05/05/2023 | 10-Q |
| 12/31/2022 | 03/03/2023 | 10-K |
| 09/30/2022 | 11/04/2022 | 10-Q |
| 06/30/2022 | 08/05/2022 | 10-Q |
| 03/31/2022 | 05/06/2022 | 10-Q |
Recent Forward Guidance [BETA]
Latest: Q4 2025 Earnings Reported 2/3/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| Q1 2026 Dividends | 0.16 | 0 | 0 | Same New | Actual: 0.16 for Q4 2025 | ||
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Freeman, Jordan Nicole | Chief Accounting Officer | Direct | Buy | 8042025 | 12.97 | 771 | 10,000 | 10,000 | Form |
| 2 | Beans, Patrick E | Direct | Buy | 5132025 | 13.59 | 2,500 | 33,974 | 475,673 | Form | |
| 3 | Harrison, Shane R | EVP & Chief Financial Officer | IRA | Buy | 2192026 | 12.27 | 8,000 | 98,162 | 98,162 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.